When is the deal expected to close?

The deal is expected to close in the first half of 2027, subject to regulatory approvals.

What are the stock symbols for Merck and Bio-Techne?

Merck's ticker is MRK, and Bio-Techne's ticker is BIO-TECHNE.

Merck KGaA to Acquire Bio-Techne in $11.3B Deal

Merck KGaA (MRK) has agreed to acquire Bio-Techne (BIO-TECHNE) for $11.3 billion in cash. The deal aims to expand Merck's life sciences and diagnostics capabilities, with closing expected in H1 2027.

June 25, 2026

2 min read

Source: InvestorsHub

Key Numbers

deal value

11.3B

target

Bio-Techne

Germany's Merck KGaA (MRK) today announced a definitive agreement to acquire U.S.-based Bio-Techne, a life sciences tools and diagnostics company, in an all-cash deal valued at $11.3 billion.

Deal Details

Total Value: $11.3 billion in cash.
Per Share Price: $85 per share, representing a premium of approximately 25% over the last closing price.
Structure: All cash.
Expected Closing: First half of 2027, subject to regulatory approvals.

Rationale

Merck aims to strengthen its life sciences segment, particularly in diagnostics and research. Bio-Techne's strong portfolio in protein and antibody testing complements Merck's existing operations.

Regulatory Challenges

The deal is expected to face antitrust reviews in the U.S. and Europe. Merck has expressed no major concerns but anticipates some scrutiny due to the deal's size.

Impact on Stocks

No immediate reaction from Merck's stock (MRK) post-announcement. Bio-Techne's stock (BIO-TECHNE) rose 20% in pre-market trading. Analysts expect a slight accretion to Merck's earnings after closing.

Frequently Asked Questions

The deal is valued at $11.3 billion in cash, or $85 per share.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.